Phaseline

Targets › PDE3

PDE3: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Respiratory; next expected readout Feb 2027.

Open in Phaseline: the race on PDE3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupTQC3721 Suspension for Inhalation
Phosphodiesterase 3/4 (PDE3/4) inhibitor
PDE3, PDE4Phase 3Chronic Obstructive Pulmonary DiseaseFeb 2027

Conditions

Chronic Obstructive Pulmonary Disease (1)

Modalities

small molecule (1)

Companies

Chia Tai Tianqing Pharmaceutical Group (1)

Related targets

PDE4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.